Upheaval at the U.S. Preventive Services Task Force may reshape coverage of preventive care by insurance, possibly leading to removal of previously covered items.

While the most favored nation initiatives have bold aims to lower the cost of drugs, the impact is limited, and in some instances unclear, a case of style over substance.

A targeted antibody‑drug conjugate shrinks tumors and slows progression in recurrent uterine cancer by ferrying potent chemotherapy directly into cancer cells.

While PBM reforms that passed earlier this year will spur further changes in the way business is conducted, it’s anti-trust legislation that could have the most impact.

Inclusion of weight loss drugs on insurer formularies is a meaningful step towards expanding access. But having a product listed doesn’t necessarily mean it’s covered.

GLP-1 drugs commonly used for weight loss and diabetes decreased the risk of cancer spreading in patients with several different types of tumors including breast and lung

E-cigarettes containing nicotine can help people quit smoking according to a new study and may be more helpful for some smokers than other nicotine products like patches.

High level resignations in protest against the push to allow sales of fruit-flavored vapes suggest a break in policy between the first and second Trump administrations.

During a tumultuous 13-month tenure at the FDA, Makary pursued a wide range of ambitious initiatives. Going forward, their status under the next commissioner is unclear.

Editing a small number of blood-forming stem cells to encode powerful antibodies turns the immune system into a living drug factory.